Intravenous landiolol, a novel β(1)-adrenergic blocker, reduces the minimum alveolar concentration of sevoflurane in women.

STUDY
OBJECTIVE: To investigate the effect of intravenous (IV) landiolol, a novel β(1)-adrenergic blocker, on the minimum alveolar concentration (MAC) of sevoflurane in adult women.
DESIGN: Prospective, randomized study.
SETTING: University hospital. PATIENTS: 42 ASA physical status 1 and 2 women, aged 24-57 years, who were scheduled to undergo elective abdominal surgery.
INTERVENTIONS: Anesthesia was induced in all patients by vital capacity rapid inhalation induction of sevoflurane. In the landiolol group, administration of landiolol began when patients took a vital-capacity breath: 0.125 mg/kg/min for one minute and then 0.04 mg/kg/min. Normal saline was administered in the control group. MEASUREMENTS: MAC was determined by a technique adapted from the conventional up-down method. MAIN
RESULTS: The MAC of sevoflurane was 2.2% ± 0.2% in the control group and 1.7% ± 0.2% in the landiolol group, a statistically significant difference (P = 0.0005).
CONCLUSIONS: IV landiolol reduces the MAC of sevoflurane in women by approximately 20%.

RCT Entities:   Population Interventions Outcomes